Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A process for the production of an orally administratable multiple-unit sustained-release pharmaceutical composition having controlled agitation-independent release, ~~comprising~~ consisting essentially of the steps of (a) combining hydroxypropylcellulose polymer having a molecular weight of 250 000 to 1 200 000 and a molar degree of substitution of at least 3 in an amount from 40 to 95% by weight with a pharmaceutically active compound and optionally with one or more pharmaceutically acceptable additional polymers and /or excipients which do not contribute significantly to a sustained-release effect, to obtain a mixture ~~of~~ containing said hydroxypropyl cellulose polymer and said active compound; (b) converting said mixture into particles having a diameter of 0.2 to 3.0 mm; (c) optionally lacquering said particles, and ~~(c)~~ ~~filling~~ (d) incorporating said particles into an orally administratable multi-unit sustained release ~~dose~~ dosage form.

2. (Currently amended) The process according to Claim 1, wherein said hydroxypropylcellulose polymer is employed in an amount from 45 to 90% by weight.

3. (Currently amended) The process according to Claim 1, wherein said hydroxypropylcellulose polymer has an average molecular weight of 350 000 to 1 150 000.

4. (Previously presented) The process according to Claim 1, wherein said particles have a maximum diameter of 0.5 to 2 mm.

5. (Previously presented) The process according to Claim 1, wherein said particles are produced by melt extrusion and/or granulation.

6. (Previously presented) The process according to Claim 1, wherein said particles are converted into said orally administratable pharmaceutical composition by conventional tableting methods.

7. (Previously presented) The process according to Claim 1, wherein said particles are in the form of pellets, granules, minitablets or grains.

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (Currently amended) ~~An agitation-independent, orally administratable multi-unit, sustained-release dose form, comprising~~ A pharmaceutical composition consisting essentially of a mixture of hydroxypropylcellulose polymer and a pharmaceutically active compound and optionally one or more pharmaceutically acceptable additional polymers and/or excipients which do not contribute significantly to a sustained-release effect, wherein said hydroxypropylcellulose polymer has a molecular weight of between 250,000 and 1,200,000 and a molar degree of substitution of ≥ 3 and is 40-95% by weight of said mixture and further wherein said mixture is granulated to ~~a particle~~ particles ~~size~~ having a diameter of between 0.2 and 3.0 mm , said particles being optionally lacquered, and said

composition being in an agitation independent, orally administratable multi unit, sustained release dosage form.

13. (Currently amended) The ~~agitation-independent, orally administratable multi-unit, sustained release dose form~~ pharmaceutical composition of claim 12, wherein said ~~dose~~ dosage form is selected from the group consisting of a capsule, a sachet and a ~~modified~~ tablet which decomposes into its constituent particles quickly after being administered.

14. (New) The dose form of claim 13 wherein said dosage form is a capsule.

15. (New) The process according to claim 1 wherein said orally administratable multi-unit sustained release dosage form is a capsule, a sachet, or a tablet which decomposes into its constituent particles quickly after being administered.

16. (New) The process of claim 15 wherein said dosage form is a capsule.